Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells

  • New preclinical data presented at AACR Annual Meeting 2022
  • Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations
  • Precision medicine approach enables potent single-agent activity in models of widely disseminated tumors

Codiak BioSciences Inc, a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new preclinical data on the Company’s engineered exosome precision medicine candidate, exoASO-C/EBPβ. The data, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, demonstrate that exoASO-C/EBPβ induces potent single-agent anti-tumor activity by repolarizing myeloid cells in the tumor and blood to induce an immune response.

“We continue to expand the application of our engineering platform to precisely target transcription factors, leveraging engineered exosomes to selectively target pathways known to play a critical role in tumor immunology,” said Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak. “Targeting distinct myeloid cell populations in the tumor microenvironment represents a novel strategy for immune oncology. These preclinical studies demonstrate a profound regression of large, disseminated tumors throughout the body following systemic dosing with exoASO-C/EBPβ. These results build on those generated by our exoASO™-STAT6 program, which also targets an oncogenic transcription factor in macrophages and is anticipated to begin Phase 1 dosing in the coming months.”

exoASO-C/EBPβ is designed to selectively deliver antisense oligonucleotides (ASOs) to down-modulate C/EBPβ, a transcription factor that regulates the immunosuppressive phenotype in tumor-associated macrophages (TAMs) and circulating myeloid derived suppressor cells (MDSCs), two subpopulations of myeloid cells. High levels of C/EBPβ expression are associated with poor prognosis in multiple cancers, including non-small cell lung cancer (NSCLC). Precise targeting of C/EBPβ in MDSCs promotes the switch of TAMs from an M2 immunosuppressive phenotype to an M1, T cell attractive, anti-tumor phenotype and plays a key role in the survival and differentiation of MDSCs in order to induce an immune response.

In vivo, systemic administration of exoASO-C/EBPβ resulted in efficient delivery of ASOs to MDSCs resulting in > 5-fold improvement in tumors and 11 to 12-fold improvement in the circulating blood compared to delivery of a non-exosome (or “free”) ASO. This precise cell targeting was coupled with effective silencing of C/EBPβ and a remodeling of the tumor microenvironment indicative of activation of an immune response. In a variety of in vivo tumor models, exoASO-C/EBPβ monotherapy generated up to 70% complete responses and, when combined with anti-PD1, significantly increased complete response rates to 90%. Notably, in a lung tumor model with widely dispersed tumors, systemic administration of exoASO-C/EBPβ resulted in resolution of tumor burden throughout the body. The profound monotherapy activity observed with exoASO-C/EBPβ in multiple tumor models refractory to anti-PD-1 therapy highlights the potential of this therapy to treat multiple anti-PD1 refractory patient populations.

About the engEx™ Platform

Codiak’s proprietary engEx Platform is designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases and to manufacture them reproducibly and at scale to pharmaceutical standards. By leveraging the inherent biology, function and tolerability profile of exosomes, Codiak is developing engEx exosomes designed to carry and protect potent drug molecules, provide selective delivery and elicit the desired pharmacology at the desired tissue and cellular sites. Through its engEx Platform, Codiak seeks to direct tropism and distribution by engineering exosomes to carry on their surface-specific targeting drug moieties, such as proteins, antibodies/fragments, and peptides, individually or in combination. Codiak scientists have identified two exosomal proteins that serve as surface and luminal scaffolds. By engineering the exosome surface or lumen and optimizing the route of administration, Codiak aims to deliver engEx exosomes to the desired cell and tissue to more selectively engage the drug target, potentially enhancing the therapeutic index by improving potency and reducing toxicity.

Source – Codiak

Leave a Reply

Your email address will not be published. Required fields are marked *